Spatiotemporal liver dynamics: How far can we take them in vitro?

Author's contributions

Hanyang Liu: Writing - review & editing, Writing - original draft, Supervision, Project administration, Investigation, Funding acquisition, Conceptualization.

Declaration of competing interest

The author received a visiting fellow scholar at the National Institutes of Health (NIH), USA. However, this work was done by the author independently without any resources from NIH, thereby not reflecting the views of the NIH or the U.S. Department of Health and Human Services. The author declares that there is no conflicts of interest.

Acknowledgements

This work was funded by National Natural Science Foundation of China (82300730) and Changzhou Science and Technology Bu-reau of China (CJ20241116). The author thanks the professional advice and academic transitioning support from Prof. Frank Tacke's and Dr. Adrien Guillot's Labs, in the Department of Hep-atology and Gastroenterology, Charité Universit € atsmedizin Berlin, Germany.

References

[1] Milani M, Starinieri F, Beretta S, et al. Spatiotemporal liver dynamics shape hepatocellular heterogeneity and impact in vivo gene engineering. J Hepatol. 2025. https://doi.org/10.1016/j.jhep.2025.06.018.PublishedonlineJuly3,2025.

[2] Liu H, Yin G, Kohlhepp MS, et al. Dissecting acute drug-induced hepatotoxicity and therapeutic responses of steatotic liver disease using primary mouse liver and blood cells in a liver-on-a-chip model. Adv Sci (Weinh). 2024; 11:e2403516. https://doi.org/10.1002/advs.202403516.

[3] Igarashi R, Oda M, Okada R, et al. Generation of human adult hepatocyte organoids with metabolic functions. Nature. 2025; 641:1248-1257. https://doi.org/10.1038/s41586-025-08861-y.

[4] Sasikumar S, Chameettachal S, KN V, Kingshott P, Cromer B, Pati F. Strategic replication of the hepatic zonation in vitro employing a biomimetic approach. ACS Appl Bio Mater. 2023; 6:5224-5234. https://doi.org/10.1021/acsabm.3c00481.

[5] Sugimoto A, Saito Y, Wang G, et al. Hepatic stellate cells control liver zonation, size and functions via R-spondin 3. Nature. 2025; 640:752-761. https://doi.org/10.1038/s41586-025-08677-w.

[6] Adlat S, Vázquez Salgado AM, Lee M, Yin D, Wangensteen KJ. Emerging and potential use of CRISPR in human liver disease. Hepatology. 2025; 82:232-253. https://doi.org/10.1097/HEP.0000000000000578.

[7] Rezvani M, Vallier L, Guillot A. Modeling nonalcoholic fatty liver disease in the dish using human-specific platforms: strategies and limitations. Cell Mol Gas-troenterol Hepatol. 2023; 15:1135-1145. https://doi.org/10.1016/j.jcmgh.2023.01.014.